Effect of Oral Alfacalcidol on Clinical Outcomes in Patients Without Secondary Hyperparathyroidism Receiving Maintenance Hemodialysis: The J-DAVID Randomized Clinical Trial
暂无分享,去创建一个
N. Yorioka | Y. Ikari | K. Iseki | T. Murohara | J. Minakuchi | S. Negi | T. Shigematsu | K. Mitsuiki | H. Hirakata | K. Tsuruya | S. Yano | M. Emoto | M. Inaba | K. Yamagata | Y. Isaka | M. Yoshiyama | T. Hosoya | T. Shoji | Y. Nishizawa | S. Okuno | M. Okamura | T. Yamakawa | E. Ishimura | T. Sugimoto | S. Nishi | M. Fukagawa | T. Nakatani | T. Kawai | R. Ando | T. Ohtake | Shuzo Kobayashi | M. Fukui | S. Ueda | Y. Tsubakihara | Masashi Suzuki | Yuzo Watanabe | Y. Tominaga | H. Kawanishi | J. Kumagai | D. Inaguma | T. Hashimoto | Y. Tsujimoto | S. Morimoto | Y. Takemoto | I. Masakane | N. Itami | A. Fujimori | K. Yokoyama | T. Kakuta | H. Honda | C. Ito | H. Hase | H. Tahara | Toru Inoue | T. Ogawa | K. Maekawa | H. Fujii | T. Mizuguchi | M. Nishikawa | K. Ohta | Kenji Tanaka | Y. Nishizawà | Toru Kawai
[1] O. Djurdjev,et al. Randomized Controlled Trial for the Effect of Vitamin D Supplementation on Vascular Stiffness in CKD. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[2] CaCO,et al. Clinical Practice Guideline for the Management of Secondary Hyperparathyroidism in Chronic Dialysis Patients , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[3] G. Pacini,et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. , 1995, Kidney international.
[4] K. Iseki,et al. Elevated non-high-density lipoprotein cholesterol (non-HDL-C) predicts atherosclerotic cardiovascular events in hemodialysis patients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[5] N. Bodyak,et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals , 2007, Proceedings of the National Academy of Sciences.
[6] Bertram L Kasiske,et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. , 2003, Circulation.
[7] D. Rodríguez‐Puyol,et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. , 2008, Kidney international.
[8] S. Otani,et al. Effect of 1,25‐dihydroxyvitamin D3 on induction of scavenger receptor and differentiation of 12‐O‐tetradecanoylphorbol‐13‐acetate‐treated THP‐1 human monocyte like cells , 1995, Journal of cellular physiology.
[9] S. Solomon,et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. , 2012, JAMA.
[10] G. Eknoyan,et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). , 2006, Kidney international.
[11] K. Wakai,et al. Overview of Regular Dialysis Treatment in Japan as of 31 December 2006 , 2008, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[12] C. Wanner,et al. The heart and vascular system in dialysis , 2016, The Lancet.
[13] L. Hsiao,et al. Vascular Klotho Deficiency Potentiates the Development of Human Artery Calcification and Mediates Resistance to Fibroblast Growth Factor 23 , 2012, Circulation.
[14] A. Go,et al. FGF23 induces left ventricular hypertrophy. , 2011, The Journal of clinical investigation.
[15] L. Wilkins. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals , 2016, Journal of the American Heart Association.
[16] K. Iseki,et al. Use of Vitamin D Receptor Activator, Incident Cardiovascular Disease and Death in a Cohort of Hemodialysis Patients , 2015, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[17] C. Park,et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] K. Moreau,et al. Cholecalciferol, Calcitriol, and Vascular Function in CKD: A Randomized, Double-Blind Trial. , 2017, Clinical journal of the American Society of Nephrology : CJASN.
[19] S. Sprague. Mortality risk among hemodialysis patients receiving different vitamin D analogs. , 2007, Kidney international.
[20] Daniel W. Jones,et al. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals , 2016, Journal of the American Heart Association.
[21] Takayuki Hamano,et al. Overview of Regular Dialysis Treatment in Japan (as of 31 December 2011) , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[22] L. Cook,et al. Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. , 1998, Cellular and molecular biology.
[23] K. Iseki,et al. Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[24] K. Kalantar-Zadeh,et al. Vitamin D receptor activation and survival in chronic kidney disease. , 2008, Kidney international.
[25] A. Go,et al. Fibroblast growth factor-23 and cardiovascular events in CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[26] C. Lam,et al. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. , 2014, Journal of the American Society of Nephrology : JASN.
[27] V. Jha,et al. A Randomized Trial of Vitamin D Supplementation on Vascular Function in CKD. , 2017, Journal of the American Society of Nephrology : JASN.
[28] M. Mohtai,et al. Smooth muscle cell proliferation in the rat coronary artery induced by vitamin D. , 1987, Atherosclerosis.
[29] M. Hernán,et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.
[30] A. Pasternack,et al. Effect of Intravenous Calcitriol on Cardiac Systolic and Diastolic Function in Patients on Hemodialysis , 1998, American Journal of Nephrology.
[31] S. Fukumoto,et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[32] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. , 2002, The Journal of clinical investigation.
[33] M. Inaba,et al. Vitamin D receptor activator and prevention of cardiovascular events in hemodialysis patients—rationale and design of the Japan Dialysis Active Vitamin D (J-DAVID) trial , 2016, Renal Replacement Therapy.
[34] A. Levin,et al. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? , 2005, Kidney international.
[35] G. Chertow,et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. , 2004, Journal of the American Society of Nephrology : JASN.
[36] Sonya J. Cable,et al. Association Between Single Gene Polymorphisms and Bone Biomarkers and Response to Calcium and Vitamin D Supplementation in Young Adults Undergoing Military Training , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[37] J. Adams,et al. 1,25-Dihydroxyvitamin D inhibits lipopolysaccharide-induced immune activation in human endothelial cells. , 2006, Clinical and experimental immunology.
[38] N. Koszewski,et al. Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. , 2002, Kidney international.
[39] E. Maccarthy,et al. 1,25‐Dihydroxyvitamin D3 and Rat Vascular Smooth Muscle Cell Growth , 1989, Hypertension.
[40] Shu Q. Liu,et al. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system , 2002 .
[41] T. Shoji,et al. In vivo effect of 1 alpha-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients. , 1988, Nephron.
[42] Y. Nishizawa,et al. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. , 1998, Circulation.
[43] K. Iseki,et al. Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder , 2013, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.
[44] T. Tabata,et al. The Effect of l-αHydroxyvitamin D3 oil Cell-Mediated Immunity in Hemodialyzed Patients , 1986 .
[45] M. Wolf,et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. , 2008, The New England journal of medicine.
[46] M. Budoff,et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. , 2006, Kidney international.